13Th Asia-Pacific Oncologists Annual Meeting October 17-19, 2016 Kuala Lumpur, Malaysia Scientific Tracks & Abstracts (Day 1)
Total Page:16
File Type:pdf, Size:1020Kb
conferenceseries.com 758th Conference 13th Asia-Pacific Oncologists Annual Meeting October 17-19, 2016 Kuala Lumpur, Malaysia Scientific Tracks & Abstracts (Day 1) Asia-Pacific Oncologists 2016 Page 25 Session Tracks Day 1 October 17, 2016 Pathophysiology of Cancer|Oropharyngeal cancer|Cancer Therapy|Nursing Oncology|Breast Oncology Session Chair Session Co-chair Michael Bilous Vincent Balaya University of Sydney, Australia University Paris Descartes, France Session Introduction Title: Breast papillary lesions: an analysis of 70 cases Mauricio Camus A, Pontifical Catholic University of Chile, Chile Title: Integration of palliative care in cancer treatment in developing countries: A global experience in Africa public health (case study of Rwanda) Christian Ntizimira, Rwanda Palliative Care and Hospice Organization/Kibagabaga Hospital, Rwanda Title: Association of VEGF Gene as Prognostic Marker in subjects with Oral Submucous Fibrosis (OSMF) of North Karnataka Population Devishree V Rai, SDM College of Dental Sciences and Hospital, India Title: Frontiers of Next Generation Sequencing in Translational Oncology Kahlil Lawless, Illumina Inc, Singapore Title: Comprehensive detection of expressed mutations by anchored multiplex PCR and next-generation sequencing Craig Pierson, ArcherDX Inc., USA Title: Overview of cosmetic outcome of hypofractionated breast irradiation vs. chest wall irradiation in Saudi female: Single institute experience AbdulAziz AlHamad,Prince Sultan Military Medical City, Saudi Arabia Title: Combretastatin A-4 inspired novel 2-aryl-3-arylamino-imidazo-pyridines/pyrazines as tubulin polymerization inhibitors, antimitotic and anticancer agents Sarita Das, KIIT University, India Title: Metastatic nonpalpable invasive lobular breast carcinoma presenting as rectal stenosis: A case report Makoto Sumazaki,Toho University School of Medicine, Japan Title: Luteal versus folicular phase surgical oophorectomy plus tamoxifen in premenopausal women with metastatic hormone receptor- positive breast cancer Syed Mozammel Hossain, Khulna Medical College and Hospital, Bangladesh Title: Sentinel Lymph Node Biopsy in cervical cancer: an update Vincent Balaya, University Paris Descartes, France Title: Interleukin-6 secreted by cancer-associated fibroblasts induces endometrial cancer growth Ivy Chung, University of Malaya, Malaysia Page 26 Mauricio Camus A, J Cancer Sci Ther 2016, 8:11(Suppl) conferenceseries.com http://dx.doi.org/10.4172/1948-5956.C1.090 13th Asia-Pacific Oncologists Annual Meeting October 17-19, 2016 Kuala Lumpur, Malaysia Breast papillary lesions: an analysis of 70 cases Mauricio Camus A Pontifical Catholic University of Chile, Chile Introduction: Papillary breast lesions are rare and constitute less than 10% of benign breast lesions and less than 1% of breast carcinomas. Objective: To analyze the clinical presentation, preoperative evaluation, and surgical and anatomopathological characteristics of the patients operated on for papillary breast lesions. Material & Methods: It is a retrospective descriptive and analytical study. We analyzed the database of patients with definitive histopathological diagnosis of papillary breast lesions operated on at our institution from January 2004 to May 2013. Results: During the period described, 70 patients with histopathological diagnosis of papillary breast lesions were operated upon. The median age was 50 years (19–86 years). Thirty-seven patients (52.8%) were symptomatic at diagnosis. Preoperative ultrasound was reported to bealtered in all patients. A mammography showed pathologic findings in only 50% of cases. All patients underwent partial mastectomy, afterneedle localization under ultrasound, if the lesion was not palpable on physical examination. The final pathological diagnosis was: benignpapillary lesion in 55 patients (78.6%) and malignant in 15 patients (21.4%). Adjuvant treatment was performed in all malignant cases. Median follow-up was 46 months (3–115 months). Conclusions: Patients with papillary breast lesions presented with symptoms in half of all cases. There was a high frequency of malignancy (21.4%), therefore surgical resection was recommended for papillary breast lesions. Biography Mauricio Camus A is a Breast Surgeon, Associate Professor, and Chief of the Department of Surgical Oncology, Pontificia Universidad Católica de Chile. He is the President of Chilean Society of Mastology during 2014-2016; President of Federation of Cancerology Societies of South America (2012-2014); Vice- president Chilean Society of Surgeons (2010-2012); President Chilean Society of Cancerology (2008-2010). He is an active member of the Board of the Senologic International Society and President of the Scientific Committee of the Latin American Federation of Mastology. He has published 18 papers in reputed international journals and 35 papers in Chilean journals. He has been serving as an Editorial Board Member of 2 repute journals. [email protected] Notes: J Cancer Sci Ther Asia-Pacific Oncologists 2016 Volume 8, Issue 11(Suppl) ISSN: 1948-5956 JCST, an open access journal October 17-19, 2016 Page 27 Christian Ntizimira, J Cancer Sci Ther 2016, 8:11(Suppl) conferenceseries.com http://dx.doi.org/10.4172/1948-5956.C1.090 13th Asia-Pacific Oncologists Annual Meeting October 17-19, 2016 Kuala Lumpur, Malaysia Integration of palliative care in cancer treatment in developing countries: A global experience in Africa public health (case study of Rwanda) Christian Ntizimira Rwanda Palliative Care and Hospice Organization/Kibagabaga Hospital, Rwanda ulti-disciplinary palliative care for patients with any cancer is rarely integrated into the public healthcare system at all Mlevels in Africa. In Rwanda, we have developed palliative care services in a district general hospital and linked these services to home care. In a public district hospital that includes 60% of the population of Kigali, we initiated adult and pediatric pain relief and palliative care programs for cancer patients with short-term technical assistance and training by foreign experts. Available services include inpatient and home care provided by physicians, nurses, social workers and pharmacists with basic training in palliative care and home hospice care provided by a private home hospice organization. As of March 2015, more than 200 patients had received inpatient palliative care. Anecdotal data indicates a high level of satisfaction by patients and family members with palliative care services provided and a reduced tendency of patients with end-stage diseases to pursue costly treatment abroad. In Africa, palliative care is not optional. It is not an extra, an ‘add-on’, a luxury or an after-thought. It is an essential component of human cancer care. To develop cancer treatments without parallel development of palliative care is a cruel injustice to the millions of cancer patients around the world who suffer needlessly. In every country, it is absolutely essential that when people talk about access to radiotherapy and cervical cancer screening and chemotherapy- all vitally important- they must also be talking in equal measure and with equal conviction about access to palliative care! Biography Christian Ntizimira is the Head of Advocacy & Research department of Rwanda Palliative Care and Hospice Organization and worked with Rwanda Ministry of Health and Consultant in Palliative Care for Human Rights Watch (HRW) in Senegal. He is a Palliative Care Expert and Educator. He pioneered integration of end of life care into health services rendered to Rwandan patients with chronic illnesses in acute care and community settings. He is a Research Collaborator & Member of the Scientific Advisory Committee of the Harvard Global Equity Initiative-Lancet Commission on Global Access to Pain Control and Palliative Care (GAPPCP). [email protected] Notes: J Cancer Sci Ther Asia-Pacific Oncologists 2016 Volume 8, Issue 11(Suppl) ISSN: 1948-5956 JCST, an open access journal October 17-19, 2016 Page 28 Devishree V Rai, J Cancer Sci Ther 2016, 8:11(Suppl) conferenceseries.com http://dx.doi.org/10.4172/1948-5956.C1.090 13th Asia-Pacific Oncologists Annual Meeting October 17-19, 2016 Kuala Lumpur, Malaysia Association of VEGF gene as prognostic marker in subjects with oral submucous fibrosis (OSMF) of North Karnataka population Devishree V Rai SDM College of Dental Sciences and Hospital, India ral cancer imposes a considerable problem worldwide being a highly lethal and disfiguring disease. According to Othe report of the World Health Organization, oral cancer is the sixth most common cancer worldwide and the most common intraoral subtype is squamous cell carcinoma. The formation or progression of oral cancer may be associated with a polymorphism of the vascular endothelial growth factor (VEGF) gene. OSCC was associated with significantly elevated serum VEGF concentration and higher level of serum VEGF also correlated with lymph node metastasis and clinical stage of OSCC. There have been association of VEGF-460C/T polymorphism in oral cancer, diabetic retinopathy, breast cancer, prostate cancer, but very few studies are known to validate the association of the VEGF gene with potentially premalignant conditions like oral submucous fibrosis. The most frequently seen polymorphism is BstUI (C to T) located at the -460th nucleotide upstream of the VEGF gene. With the malignant transformation rate of OSMF being 7-30%, VEGF gene -460C/T can become an important prognostic marker. The aim of our study was to assess the polymorphic